The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Preoperative radiotherapy for esophageal carcinoma
Open accessAbstract
BACKGROUND: The existing randomized evidence has failed to conclusively demonstrate the benefit or otherwise of preoperative radiotherapy in treating patients with potentially resectable esophageal carcinoma. OBJECTIVES: This meta-analysis aimed to assess whether there is benefit from adding radiotherapy prior to surgery and whether or not any pre-defined patient subgroups benefit more or less from preoperative radiotherapy SEARCH STRATEGY: MEDLINE and CancerLit searches were supplemented by information from trial registers and by hand searching relevant meeting proceedings and by discussion with relevant trialists, organisations and industry. The search strategy was run again in MEDLINE, EMBASE and the Cochrane Library on 30th April 2001, two years after original publication. No new trials were found. The search strategy was re-run August 2002 and August 2003 on MEDLINE, EMBASE , CancerLit and The Cochrane Library, and July 2004 and 2005 on MEDLINE, EMBASE and the Cochrane Library. No new relevant trials were identified on any of these occasions. SELECTION CRITERIA: Trials were eligible for inclusion in this meta-analysis provided they randomized patients with potentially resectable carcinoma of the esophagus (of any histological type) to receive radiotherapy or no radiotherapy prior to surgery. Trials must have used a randomization method which precluded prior knowledge of treatment assignment and completed accrual by December 1993, to ensure sufficient follow-up by the time of the first analysis (September 1995). DATA COLLECTION AND ANALYSIS: A quantitative meta-analysis using updated data from individual patients from all properly randomized trials (published or unpublished) comprising 1147 patients (971 deaths) from five randomized trials. This approach was used to assess whether preoperative radiotherapy improves overall survival and whether it is differentially effective in patients defined by age, sex and tumour location. MAIN RESULTS: With a median follow-up of 9 years, in a group patients with mostly squamous carcinomas, the hazard ratio (HR) of 0.89 (95% CI 0.78-1.01) suggests an overall reduction in the risk of death of 11% and an absolute survival benefit of 3% at 2 years and 4% at 5 years. This result is not conventionally statistically significant (p=0.062). No clear differences in the size of the effect by sex, age or tumor location were apparent. AUTHORS' CONCLUSIONS: Based on existing trials, there was no clear evidence that preoperative radiotherapy improves the survival of patients with potentially resectable esophageal cancer. These results indicate that if such preoperative radiotherapy regimens do improve survival, then the effect is likely to be modest with an absolute improvement in survival of around 3 to 4%. Trials or a meta-analysis of around 2000 patients (90% power, 5% significance level) would be needed to reliably detect such an improvement (from 15 to 20%).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Cited by
Sjoquist, K. M., Burmeister, B. H., Smithers, B. M., Zalcberg, J. R., Simes, R. J., Barbour, A., & Gebski, V. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70142-5 · Cited by 1,647
Gebski, V., Burmeister, B., Smithers, B. M., Foo, K., Zalcberg, J., & Simes, J. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70039-6 · Cited by 1,158
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Lordick, F., Mariette, C., Haustermans, K., Obermannová, R., & Arnold, D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw329 · Cited by 1,098
Guidelines for the management of oesophageal and gastric cancer
Allum, W. H., Blazeby, J. M., Griffin, S. M., Cunningham, D., Jankowski, J. A., Wong, R., & On behalf of the Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, T. B. S. O. G. A. T. B. A. O. S. O. (2011) · Gut · doi:10.1136/gut.2010.228254 · Cited by 793
Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities
Mariette, C., Piessen, G., & Triboulet, J.-P. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70172-9 · Cited by 475
Metadata
- Authors
- Arnott, S. J., Duncan, W., Gignoux, M., Girling, D., Hansen, H., Launois, B., Nygaard, K., Parmar, M. K., Rousell, A., Spiliopoulos, G., Stewart, L., Tierney, J., Wang, M., Rhugang, Z., & Oeosphageal Cancer Collaborative Group
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2005-10-19
- Volume
- 2012
- Issue
- 3
- Pages
- CD001799-CD001799
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2110459969
- Cited by
- 165
- References
- 1
- FWCI
- 8.24
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preoperative radiotherapy for esophageal carcinoma. https://app.cochat.ai/papers/10.1002/14651858.cd001799.pub2
- The paper
- Arnott, S. J., Duncan, W., Gignoux, M., Girling, D., Hansen, H., Launois, B., Nygaard, K., Parmar, M. K., Rousell, A., Spiliopoulos, G., Stewart, L., Tierney, J., Wang, M., Rhugang, Z., & Oeosphageal Cancer Collaborative Group. (2005). Preoperative radiotherapy for esophageal carcinoma. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd001799.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.